Drug Profile
Amphotericin B - Lypro Biosciences
Alternative Names: AMB - Lypro Biosciences; AMB-NanoDiskLatest Information Update: 12 Sep 2023
Price :
$50
*
At a glance
- Originator Lypro Biosciences
- Developer Children's Hospital Oakland Research Institute; Lypro Biosciences
- Class Antifungals; Antiprotozoals; Macrolides
- Mechanism of Action Cell membrane permeability enhancers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Aspergillosis; Leishmaniasis
Most Recent Events
- 12 Sep 2023 Discontinued - Preclinical for Aspergillosis in USA (unspecified route)
- 12 Sep 2023 Discontinued - Preclinical for Leishmaniasis in USA (unspecified route)
- 28 Aug 2020 No recent reports of development identified for preclinical development in Leishmaniasis in USA